Detalhe da pesquisa
1.
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
Blood
; 140(16): 1790-1802, 2022 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35981465
2.
A tumor-targeted immune checkpoint blocker.
Proc Natl Acad Sci U S A
; 116(32): 15889-15894, 2019 08 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31332018
3.
Applications of genetic code expansion technology in eukaryotes.
Protein Cell
; 2023 Oct 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37847216
4.
A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.
Theranostics
; 12(18): 7788-7803, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36451856
5.
Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.
ACS Synth Biol
; 10(5): 1176-1183, 2021 05 21.
Artigo
Inglês
| MEDLINE | ID: mdl-33856201
6.
Synthesis of precision antibody conjugates using proximity-induced chemistry.
Theranostics
; 11(18): 9107-9117, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34522229
7.
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research.
Front Immunol
; 11: 176, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32194541
8.
Engineered T Cell Therapy for Cancer in the Clinic.
Front Immunol
; 10: 2250, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31681259
9.
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
J Exp Clin Cancer Res
; 38(1): 332, 2019 Jul 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31362764